Dexmedetomidine: as safe as safe can be

Seminars in Anesthesia, Perioperative Medicine and Pain

Volumn 25, Issue 2, 2006, Pages 77-83

  Wagner, Deborah S ^a   Brummett, Chad M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adverse events; Alpha 2 adrenoceptor agonists; Clonidine; Dexmedetomidine; Side effects

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ATIPAMEZOLE; CLONIDINE; DEXMEDETOMIDINE; MIDAZOLAM; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PHENYLEPHRINE; PLACEBO;

ADRENERGIC ACTIVITY; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CANCER PAIN; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; ELECTROCARDIOGRAPHY; ENDOCRINE SYSTEM; EPIDURAL ANESTHESIA; EPILEPTIC DISCHARGE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; HYPNOSIS; HYPOTENSION; MEDICAL LITERATURE; NEUROMUSCULAR BLOCKING; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESPIRATORY SYSTEM; SEDATION; SEIZURE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VENTILATED PATIENT;

EID: 33744516328     PISSN: 02770326     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sane.2006.02.003     Document Type: Article

References (60)

1. Murrell J.C., and Hellebrekers L.J. Medetomidine and dexmedetomidine. a review of cardiovascular effects and antinociceptive properties in the dog. Vet Anaesth Analg 32 (2005) 117-127
2. Triltsch A.E., Welte M., von Homeyer P., et al. Bispectral index-guided sedation with dexmedetomidine in intensive care. a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med 30 (2002) 1007-1014
3. Bloor B.C., Ward D.S., Belleville J.P., et al. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 77 (1992) 1134-1142
4. Martin E., Ramsay G., Mantz J., et al. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med 18 (2003) 29-41
5. Lidbrink P. The effect of lesions of ascending noradrenaline pathways on sleep and waking in the rat. Brain Res 74 (1974) 19-40
6. Gordh Jr. T., Post C., and Olsson Y. Evaluation of the toxicity of subarachnoid clonidine, guanfacine, and a substance P-antagonist on rat spinal cord and nerve roots. light and electron microscopic observations after chronic intrathecal administration. Anesth Analg 65 (1986) 1303-1311
7. Mangano D. Peri-operative cardiovascular morbidity. new developments. Baillieres Clin Anesthesiol 13 (1999) 335-338
8. Oliver M.F., Goldman L., Julian D.G., et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease. the European Mivazerol Trial (EMIT). Anesthesiology 91 (1999) 951-961
9. McSPI-Europe Research Group. Perioperative sympatholysis. Beneficial effects of the alpha 2-adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. Anesthesiology 86 (1997) 346-363
10. Wijeysundera D.N., Naik J.S., and Beattie W.S. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications. a meta-analysis. Am J Med 114 (2003) 742-752
11. Langer S.Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32 (1980) 337-362
12. Drew G.M., and Whiting S.B. Evidence for two distinct types of postsynaptic alpha-adrenoceptor in vascular smooth muscle in vivo. Br J Pharmacol 67 (1979) 207-215
13. Ebert T.J., Hall J.E., Barney J.A., et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 93 (2000) 382-394
14. Kamibayashi T., and Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 93 (2000) 1345-1349
15. Bhana N., Goa K.L., and McClellan K.J. Dexmedetomidine. Drugs 59 (2000) 263-268 discussion 269-270
16. Yerramilli U, Mayer M, Johnson P, et al: Human in vivo and in vitro metabolism of dexmedetomidine. ISSX Proceedings;15:110
17. Cunningham F., Baugham V., Tonkovich L., et al. Pharmacokinetics of dexmedetomidine in patients with hepatic failure [abstract]. Clin Pharmacol Ther 65 (1999) 128
18. Precedex P.I. Dexmedetomidine Hydrochloride Injection (2000), Abbott Laboratories, Abbott Park, IL
19. Eisenach J.C., Castro M.I., Dewan D.M., et al. Intravenous clonidine hydrochloride toxicity in pregnant ewes. Am J Obstet Gynecol 160 (1989) 471-476
20. Soares de Moura R., Rios A.A., de Oliveira L.F., et al. The effects of nitric oxide synthase inhibitors on the sedative effect of clonidine. Anesth Analg 93 (2001) 1217-1221
21. Soares de Moura R., and Cardoso L. Involvement of endothelium on the anti-hypertensive effect of clonidine. J Vasc Res 34 (1997) 38
22. Mason S.T., and Angel A. Anaesthesia. the role of adrenergic mechanisms. Eur J Pharmacol 91 (1983) 29-39
23. Nishiyama T., and Hanaoka K. The synergistic interaction between midazolam and clonidine in spinally-mediated analgesia in two different pain models of rats. Anesth Analg 93 (2001) 1025-1031
24. Salonen M., Reid K., and Maze M. Synergistic interaction between alpha 2-adrenergic agonists and benzodiazepines in rats. Anesthesiology 76 (1992) 1004-1011
25. Murai T., Kyoda N., Misaki T., et al. Effects of clonidine on intravenous sedation with midazolam. Anesth Prog 42 (1995) 135-138
26. Scheinin H., MacDonald E., and Scheinin M. Behavioural and neurochemical effects of antipamezole, a novel alpha 2-adrenoceptor antagonist. Eur J Pharmacol 151 (1988) 35-42
27. Scheinin H., Aantaa R., Anttila M., et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole. a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology 89 (1998) 574-584
28. Angst M.S., Ramaswamy B., Davies M.F., et al. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Anesthesiology 101 (2004) 744-752
29. Filos K.S., Goudas L.C., Patroni O., et al. Hemodynamic and analgesic profile after intrathecal clonidine in humans. A dose-response study. Anesthesiology 81 (1994) 591-601 discussion 27A-28A
30. Eisenach J.C., DuPen S., Dubois M., et al., The Epidural Clonidine Study Group. Epidural clonidine analgesia for intractable cancer pain. Pain 61 (1995) 391-399
31. Walker S.M., Howard R.F., Keay K.A., et al. Developmental age influences the effect of epidural dexmedetomidine on inflammatory hyperalgesia in rat pups. Anesthesiology 102 (2005) 1226-1234
32. Asano T., Dohi S., Ohta S., et al. Antinociception by epidural and systemic alpha(2)-adrenoceptor agonists and their binding affinity in rat spinal cord and brain. Anesth Analg 90 (2000) 400-407
33. Miyazaki Y., Adachi T., Kurata J., et al. Dexmedetomidine reduces seizure threshold during enflurane anaesthesia in cats. Br J Anaesth 82 (1999) 935-937
34. Sturaitis M., Ford E., Palac S., et al. Effect of dexmedetomidine on operative conditions and electorcorticograph responses during asleep craniotomy for seizure focus resection. Anesthesiology 99 (2003) A290
35. Talke P.O., Caldwell J.E., Richardson C.A., et al. The effects of dexmedetomidine on neuromuscular blockade in human volunteers. Anesth Analg 88 (1999) 633-639
36. Venn R.M., Bradshaw C.J., Spencer R., et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 54 (1999) 1136-1142
37. Talke P., Richardson C.A., Scheinin M., et al. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg 85 (1997) 1136-1142
38. Riker R.R., and Fraser G.L. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 25 (2005) 8S-18S
39. Venn M., Newman J., and Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 29 (2003) 201-207
40. Shehabi Y., Ruettimann U., Adamson H., et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients. sedative and cardiovascular effects. Intensive Care Med 30 (2004) 2188-2196
41. Dasta J.F., Kane-Gill S.L., and Durtschi A.J. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. Ann Pharmacother 38 (2004) 1130-1135
42. Peden C.J., Cloote A.H., Stratford N., et al. The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anaesthesia 56 (2001) 408-413
43. Ingersoll-Weng E., Manecke Jr. G.R., and Thistlethwaite P.A. Dexmedetomidine and cardiac arrest. Anesthesiology 100 (2004) 738-739
44. Herr D.L., Sum-Ping S.T., and England M. ICU sedation after coronary artery bypass graft surgery. dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 17 (2003) 576-584
45. Lou Y.P., Franco-Cereceda A., and Lundberg J.M. Variable alpha 2-adrenoceptor-mediated inhibition of bronchoconstriction and peptide release upon activation of pulmonary afferents. Eur J Pharmacol 210 (1992) 173-181
46. Groeben H., Mitzner W., and Brown R.H. Effects of the alpha2-adrenoceptor agonist dexmedetomidine on bronchoconstriction in dogs. Anesthesiology 100 (2004) 359-363
47. Nishida T., Nishimura M., Kagawa K., et al. The effects of dexmedetomidine on the ventilatory response to hypercapnia in rabbits. Intensive Care Med 28 (2002) 969-975
48. Roberge R.J., Kimball E.T., Rossi J., et al. Clonidine and sleep apnea syndrome interaction. antagonism with yohimbine. J Emerg Med 16 (1998) 727-730
49. Venn R.M., Hell J., and Grounds R.M. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 4 (2000) 302-308
50. Belleville J.P., Ward D.S., Bloor B.C., et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 77 (1992) 1125
51. Wahlander S., Frumento R.J., Wagener G., et al. A prospective, double-blind, randomized, placebo-controlled study of dexmedetomidine as an adjunct to epidural analgesia after thoracic surgery. J Cardiothorac Vasc Anesth 19 (2005) 630-635
52. Gellai M. Modulation of vasopressin antidiuretic action by renal alpha 2-adrenoceptors. Am J Physiol 259 (1990) F1-F8
53. Gutkowska J., Mukaddam-Daher S., and Tremblay J. The peripheral action of clonidine analog ST-91. involvement of atrial natriuretic factor. J Pharmacol Exp Ther 281 (1997) 670-676
54. Venn R.M., and Grounds R.M. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit. patient and clinician perceptions. Br J Anaesth 87 (2001) 684-690
55. Maze M., Virtanen R., Daunt D., et al. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis. in vivo and in vitro studies. Anesth Analg 73 (1991) 204-208
56. Aho M., Scheinin M., Lehtinen A.M., et al. Intramuscularly administered dexmedetomidine attenuates hemodynamic and stress hormone responses to gynecologic laparoscopy. Anesth Analg 75 (1992) 932-939
57. Desborough J.P. The stress response to trauma and surgery. Br J Anaesth 85 (2000) 109-117
58. Venn R.M., Bryant A., Hall G.M., et al. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 86 (2001) 650-656
59. Jorden V.S., Pousman R.M., Sanford M.M., et al. Dexmedetomidine overdose in the perioperative setting. Ann Pharmacother 38 (2004) 803-807
60. Litovitz T.L., Klein-Schwartz W., Rodgers Jr. G.C., et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 20 (2002) 391-452